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INTRODUCTION
Primary breast cancer is one of the most common cancer
for women. The dissemination of metastasis is the leading
cause of breast cancer fatality. The metastatic process of malig-
nant cells involves cell proliferation and cell-cell interactions,
in which epithelial membrane protein 3 (EMP3) is thought to
be involved (1). 
The myelin-related gene EMP3 belongs to the peripheral
myelin protein 22-kDa (PMP22) gene family of small hy-
drophobic membrane glycoproteins, which include four close-
ly related members, PMP22, EMP1 (TMP), EMP2 (XMP),
and EMP3 (YMP), as well as an additional and more distant,
member, MP20 (2). The EMP3 gene is located on the 19q13.3
band, which encodes a protein similar to PMP22, EMP1 and
EMP2 with approximately 40% of amino acids (1). EMP3
has high transcriptional expression in peripheral blood leuko-
cytes, ovary, intestine and various embryonic tissues (1). The
function of the EMP3 protein is largely unknown. But it may
be involved in regulating cell proliferation and cell-cell inter-
actions, based on the available data for PMP22 and EMP1
which are the best-characterized members of the family (3).
Recent reports showed that overexpression of EMP3 positive-
ly associated with the invasive status of human mammary
carcinoma cell lines (4-6).
It has emerged that epigenetic events can lead to gene inac-
tivation that contributes to human neoplasia. The most im-
portant mechanism in mammalian cells is DNA methyla-
tion, the covalent addition of a methyl group to the 5′ posi-
tion of cytosine, predominantly within the CpG dinucleotide
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EMP3 Overexpression in Primary Breast Carcinomas is not Associated
with Epigenetic Aberrations
Epithelial membrane protein 3 (EMP3) is a trans-membrane signaling molecule with
important roles in the regulation of apoptosis, differentiation and invasion of cancer
cells, but the detailed is largely still unknown. We analyzed the mRNA levels and
methylation statuses of EMP3 in 63 primary breast carcinomas and assessed their
correlations with clinicopathologic variables. The expression of EMP3 mRNA in
primary breast carcinomas was significantly higher than the expression of 20 nor-
mal breast tissues (p<10
-7). EMP3 overexpression in breast carcinomas was sig-
nificantly related to histological grade III (p=3.9× ×10
-7), lymph node metastasis (p=
0.003), and strong Her-2 expression (p=3.3× ×10
-6). Hypermethylation frequencies
of EMP3 were detected in 36.5% of breast carcinomas by methylation-specific poly-
merase chain reaction. However, no significant correlations were found between
methylation status of EMP3 and mRNA expression levels as well as other clinical
parameters. In conclusion, EMP3 may be a novel marker of tumor aggressiveness.
Overexpression of EMP3 in primary breast carcinoma is not associated with DNA
methylation. 
Key Words : PMP22/EMP/MP20 Gene Family; Metastasis; Breast Neoplasms; DNA Methylation; Epigenet-
ics, Genetic
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Accepted : 15 April 2008(7). An online search for CpG islands (http://ccnt.hsc.usc.
edu/cpgislands/) in the 5′ region of the EMP3 gene (Gen-
Bank accession number, NM001425) revealed a typical CpG
island on the start site of the transcripton. It indicated that
hypermethylation of the promoter regions of EMP3 likely
plays an important role in the regulation of their mRNA
levels in malignant tumors. Alaminos et al. (8) showed that
the hypermethylation of the promoter region of the EMP3
gene was present in 24% of 116 neuroblastic primary tumors
and 39% of 41 gliomas. On the contrary, Li et al. (9) recently
reported that methylation alone does not mediate transcrip-
tional down-regulation of EMP3 in oligodendroglial tumors,
because their study with 29 oligodendroglial tumors showed
no correlation between transcript level and methylation sta-
tus. The methylation status of the EMP3 gene is still unknown
in other human tumors. In the present study, we tried to ana-
lyze the methylation status of the EMP3 gene as well as its
correlation with mRNA levels in human primary breast car-
cinoma.
MATERIALS AND METHODS
Tissue samples
Primary breast carcinoma samples (n=63) and normal
breast tissues (n=20) were obtained from patients who were
diagnosed with T1-T3, N0-N2 (stage I-IIIA) breast carci-
noma and had been treated with curative resectional surgery
between June 2004 and March 2006, in Shandong Cancer
Hospital and Institute (Jinan, China). Among them, 9 pati-
ents had stage I, 25 patients had stage IIA, 13 patients had
stage IIB, and 16 patients had stage IIIA disease. The medi-
an age of the patients was 51 yr (range, 32-80). There were
34 node-negative and 29 node-positive patients (12 with
one to three positive nodes, and 17 with more than three
positive nodes). Histological subtypes included 43 invasive
ductal, 6 invasive lobular, 6 mixed type (ductal/lobular), 7
mucinous carcinomas and 1 ductal carcinoma in situ, which
were classified according to the WHO classification (10). All
the breast tissue samples were collected from patients, who
had neither chemotherapy nor radiotherapy before opera-
tion. They were collected with the informed consent of all
patients. The study was approved by the ethics committees
of Shandong Cancer Hospital. The collected specimens were
snap-frozen in liquid nitrogen and kept at -80℃.
Immunohistochemical analysis
Standard immunohistochemical detection, with minor
modifications, was performed with archival paraffin embed-
ded breast tumor tissues and corresponding nonmalignant
breast tissues. In brief, 4 μ m thick histological sections were
mounted on 0.1% poly-L-lysine treated slides, dried over-
night at 37℃, and subsequently deparaffinized and rehy-
drated. Protein expressions in malignant and nonmalignant
breast tissues were detected with specific antibodies against
the estrogen receptor (ER) (Zymed, San Francisco, CA, U.S.A.;
prediluted monoclonal mouse anti-human estrogen receptor
clone 1D5, incubated for 18 hr at 4℃), the progesterone
receptor (PR) (Zymed; prediluted monoclonal mouse anti-
human progesterone receptor clone PR-2C5, incubated for
18 hr at 4℃), Her-2 (Zymed; prediluted monoclonal mouse
anti-human Her-2 clone TAB250, incubated for 30 min at
37℃), p53 (Zymed; prediluted monoclonal mouse anti-
human p53 protein clone BP53.12, incubated for one hour
at 37℃), and Ki-67 (Zymed; prediluted monoclonal mouse
anti-human Ki-67 antigen clone 7B11, incubated for one
hour at 37℃). In addition, positive and negative controls for
each marker were routinely performed during experiments.
Sections were then processed using the Histostain-SP kits
according to the manufacturer’s recommendations (Zymed).
Interpretation of the staining was carried out according to
the usual criteria (11) by two independent blinded observers.
If any discrepancies between classifications of samples arose,
they were reviewed and the final results reached by consen-
sus. In brief, ER, PR, and p53 were scored for the immuno-
histochemical signal as follows: weak (1+), moderate (2+),
and strong (3+) staining in >10% of the tumor cells or absent
(0). Levels of Her-2 protein expression were evaluated semi-
quantitatively using Zymed evaluation guidelines, as follows:
no staining or membrane staining in less than 10% of the
tumor cells (0), weak, incomplete membrane staining in more
than 10% of the tumor cells (1+), weak or moderate com-
plete membrane staining in more than 10% of the tumor
cells (2+), and strong, complete membrane staining in more
than 10% of the tumor cells (3+). Further, for Ki-67 expres-
sion we evaluated the percentage of cells stained.
RNA extraction and reverse transcription
Total RNA was extracted from frozen tissues using the Tri-
zol reagent (Invitrogen, Carlsbad, CA, U.S.A.) following the
manufacturer’s instructions. RNA was treated with DNase
and purified using the RNeasy mini kit (Qiagen, Hilden,
Germany). Purified RNA was eluted in 30 μ L of the RNA
storage solution (Ambion, Austin, TX, U.S.A.) and stored
at -80℃. The total RNA was quantified by UV-spectroscopy
(U-3000 Spectrophotometer, Hitachi, Tokyo, Japan). cDNA
synthesis was conducted using the high capacity cDNA ar-
chive kit (Applied Biosystems, Foster City, CA, U.S.A.) accord-
ing to the manufacturer’s instructions. The cDNA samples
were used for reverse transcriptase-polymerase chain reaction
(RT-PCR) analysis.
Semi-quantitative RT-PCR
The primers of EMP3 gene were designed by the soft-
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001425). The upward and downward primers were designed
to span two exons to avoid any amplification of genomic DNA.
The primer pairs of EMP3 were 5′ -CGA GAA TGG CTG
GCT GAA G-3′ , 5′ -GCC ACG CTG GTG CAA AG-3′ , (156
bp). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
mRNA was also amplified in the same PCR reactions as an
internal control using the following primers: 5′ -GAA GGT
GAA GGT CGG AGT C-3′ , 5′ -GAA GAT GGT GAT GGG
ATT TC-3′ , (226 bp, designed by Applied Biosystems). For
semi-quantitative RT-PCR analysis, 1 μ L of cDNA was added
in a tube containing 10×Reaction Buffer 1 μ L, 4×10 mM
dNTP 0.4 μ L, 10 μ M of each primer 0.5 μ L, 5 U/μ L Taq DNA
polymerase 0.1 μ L (Promega, Madison, WI, U.S.A.) in a final
volume of 10 μ L (12). Cycling conditions were denaturation at
94℃ for 5 min, then 35 cycles of PCR (94℃, 30 sec; 60℃,
30 sec; and 72℃, 30 sec), followed by a final extension of 72℃
for 10 min. The amplification products were resolved by 3%
agarose gel electrophoresis and visualized by ethidium bro-
mide staining.
Quantitative real-time PCR
Quantitative real-time PCR was carried out using the spe-
cific primers as mentioned above. GAPDH mRNA was also
amplified as an internal control. Briefly, 2 μ L of cDNA was
used to determine gene expression levels by the ABI PRISM
�
7000HT Sequence Detection Systems (Applied Biosystems).
It was amplified in the 25 μ L reaction including 2×SYBR
Premix Ex TaqTM 12.5 μ L (Takara, Shiga, Japan), 10 μ Mo f
each primer 0.5 μ L, 50×ROX Reference Dye 0.5 μ L and H2O
9 μ L. Cycling conditions included a hot start (15 sec, 95℃),
followed by 40 cycles of 95℃, 10 sec and 60℃, 40 sec. For
analysis, a threshold was set for the change in fluorescence
at a point in the linear PCR amplification phase. Melt curve
analysis was performed to ensure a single product species. All
experiments were done in duplicate for both target gene and
internal control and repeated three independent times. For
the CTcalculation to be valid, the amplification efficiencies
of the target and reference must be approximately equal. The
standard curves used to determine relative expression were
obtained by running real-time PCR for a diluted sample, for
example, to 1:1, 1:10, 1:100, and 1:1,000. After control for
equal PCR efficiency of target genes and internal controls,
relative gene expressions were presented with the compara-
tive Ct method of quantification (13). Briefly, this technique
uses the formula 2-C T to calculate the relative expression of
target genes normalized to a calibrator. The threshold cycle
(CT) indicates the cycle number at which the amount of ampli-
fied target reaches a fixed threshold. The level of genes was
calculated by comparing  CT values of the sample ( CT=
CT [target gene]-CT [GAPDH gene]) to that of the calibra-
tor; that is  CT=C T (tumor sample)- CT (calibrator). 
DNA preparation and sodium bisulphate modification
Genomic DNA from tissue specimens was isolated accord-
ing to a standard proteinase K digestion and phenol/chloro-
form extraction protocol with some modifications (14). In
brief, the materials were grounded to a fine powder under
liquid nitrogen. Frozen pulverized powders of the specimens
were incubated overnight at 52℃, in 500 μ L lytic solution
(10 mM Tris-HCl pH 8.0, 0.1 M EDTA, 0.5% SDS) contain-
ing proteinase K (Roche, Indianapolis, IN, U.S.A.). These
were followed by extraction with equal volumes of phenol:
chloroform:isoamyl alcohol (25:24:1). DNA was ethanol pre-
cipitated at -20℃, washed with 70% ethanol, dried and
resuspended in TE buffer. The DNA concentrations were
calculated according to the OD 260 nm readings.
For DNA methylation analysis, sodium bisulfite modifi-
cation of genomic DNA was performed, as described previ-
ously with minor modifications (15). Briefly, 1 μ g of genomic
DNA was denatured at 42℃ for 30 min, in a total volume
of 50 μ L containing NaOH (final concentration, 0.2 M). After
the addition of 30 μ L freshly prepared 10 mM hydroquinone
(Sigma, St. Louis, MO, U.S.A.) and 520 μ L of 3 M sodium
bisulfite (Sigma) at pH 5.0, the samples were incubated 16
hr at 55℃ in the dark. Afterward, modified DNA was puri-
fied using Wizard DNA clean-up resin (Promega A7280),
and DNA was desulfonated in 0.3 M NaOH at 37℃for 15
min. Treatment of genomic DNA with sodium bisulfite con-
verts unmethylated cytosines (but not methylated cytosines)
to uracil, which are then converted to thymidine during the
subsequent PCR step, giving sequence differences between
methylated and unmethylated DNA. The converted DNA
was precipitated at -20℃, overnight in ice-cold 100% etha-
nol containing ammonium acetate (final concentration, 3 M)
and 10 μ g of glycogen. DNA was resuspended in deionized
water, and used immediately or stored at -20℃. 
Methylation-specific PCR (MSP)
Bisulfite-modified DNA was amplified with primers spe-
cific for methylated or unmethylated sequences. The methy-
lated-specific and unmethylated-specific primers (8) covered
the transcription start site of EMP3. The methylated DNA
of EMP3 (144 bp) was amplified using M set primers, 5′ -
GAC GTA GAA GGA GAG CGA GC-3′ (sense), 5′ -CCT
CGC TCG AAC CTC CGT A-3′ (antisense), and the unme-
thylated DNA of EMP3 (149 bp) was amplified using U set
primers, 5′ -GAA GAG ATG TAG AAG GAG AGT GAG
T-3′ (sense), 5′ -CTT ATC CCT CAC TCA AAC CTC CAT
A-3′ (antisense). The PCR mixture contained 2×GC buffer
5 μ L (Takara), 4×10 mM dNTP 0.4 μ L, 10 μ M of each primer
0.5 μ L, 5 U/μ L Takara LA Taq DNA polymerase 0.1 μ L( T a -
kara), and 2 μ L bisulfite-modified DNA. Amplification was
carried out as follows: after initial denaturation at 95℃ for
5 min, 40 cycles of amplification at 95℃ for 30 sec, 58℃
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sec, followed by a final extension of 72℃ for 10 min. DNA
from peripheral blood lymphocytes of healthy individuals
was used as a positive control for unmethylated alleles. DNA
from peripheral normal blood lymphocytes treated in vitro
with SssI methyltransferase (New England Biolabs, Ipswich,
MA, U.S.A.) was used as a positive control for methylated
alleles. Ten μ L of each PCR reaction were loaded and run onto
3% agarose gels stained with ethidium bromide and visualized
under UV illumination. The PCR for all samples demon-
strating methylation status of the EMP3 gene was repeated
to confirm these results.
Statistical analysis
Descriptive statistics, such as mean, standard deviation,
and percentage were used to summarize a patient’s data and
gene expression or methylation status. The immunohistolog-
ical markers were defined into dichotomous variables on the
basis of the staining index such as negative/reduced expres-
sion levels (scores 0, 1, and 2) and positive/maximum stain-
ing (score 3) for ER, PR, Her-2 proteins. To p53 protein, the
expression level was categorized as negative (scores 0 and 1)
or positive (scores 2 and 3). The comparison of EMP3 mRNA
levels among various subgroups such as tumor sizes, histologic
grade, and lymph node status was calculated using the Kruskal-
Wallis test. The EMP3 mRNA expression levels between
different sex, immunohistological, and methylation status
teams were evaluated by using the Mann-Whitney test. The
correlations of the methylation statuses of EMP3 with clini-
copathologic parameters were analyzed by chi-square test.
Statistical significance was assumed for p<0.05. The statisti-
cal tests were performed using the statistical software package
SPSS, version 12.0 (LEAD Technologies, Athens, GA, U.S.A.).
RESULTS
Correlation of EMP3 mRNA levels with clinicopathologic
parameters in primary breast carcinoma
The mRNA levels of EMP3 were analyzed in all the 63
primary breast carcinomas and the 20 normal breast tissues
by conventional RT-PCR (Fig. 1A). The results showed that
the mRNA of EMP3 was over-expressed in breast carcinomas
as compared with in normal breast tissues. EMP3 expression
status determined by real-time PCR assay is shown accord-
ing to the various clinical, pathological, and biological param-
eters in Table 1. The expression of EMP3 mRNA in prima-
ry breast carcinomas was significantly higher than the expres-
sion of 20 normal breast tissues (p<10-7). Furthermore, EMP3
overexpression in primary breast carcinomas was significant-
ly related to histological grade III (p=3.9×10-7), lymph node
metastasis (p=0.003), and strong Her-2 expression (p=3.3
×10-6). Other parameters such as age, menopausal status,
histological subtype and macroscopic tumor size did not show
significant correlations with EMP3 mRNA levels. 
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GAPDH
EMP3 150 bp
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TB20 TB23 TB26 TB27 TB41 TB47 TB50 TB56 TB57
GAPDH
EMP3 150 bp
A
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149 bp 144 bp
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Fig. 1. Expression and methylation analyses of EMP3 in primary breast carcinomas. (A) Semi-quantitative RT-PCR analysis showing EMP3
mRNA is over-expressed in primary breast carcinoma (TB) as compared with their corresponding nonmalignant tissues (NB). (B) Methy-
lation analysis of EMP3 in primary breast carcinomas (TB) by methylation-specific PCR. 
Lane U, unmethylated; Lane M, methylated. Data in (A, B) are representative of two independent experiments.The methylation statuses of EMP3 and their correlation
with clinical-pathological data in primary breast carcinoma
The frequencies of methylation of EMP3 were determined
in the 63 resected primary breast carcinomas and in the 20
corresponding nonmalignant breast tissues by methylation-
specific PCR (Fig. 1B). Twenty-three of 63 (36.5%) tumors
showed EMP3 methylation. In the normal breast tissues,
methylation of EMP3 was not detected. The incomplete
methylation form of EMP3 was detected in 82.6% (19/23)
of methylated samples in breast carcinomas. Statistical analy-
sis showed that there were no significant links between methy-
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Number p value EMP3 mRNA levels
(mean±SD)
Age 0.543*
≤50 26 2.11±1.98
>50 37 2.43±2.13
Menopausal status 0.754*
Premenopausal 28 2.15±1.92
Parimenopausal 3 1.79±1.40
Postmenopausal 32 2.48±2.25
Lymph node status 0.003
�
0 34 1.92±1.62
1-3 12 1.41±1.67
>3 17 3.67±2.48
Histological grade 3.9×10
-7�
I 3 0.97±0.93
II 42 1.73±1.84
III 18 3.62±2.03
Tumor type 0.839
�
Ductal 43 2.40±2.15
Lobular 6 1.98±1.84
Others 14 2.12±1.96
Tumor diameter (cm) 0.929
�
≤2 15 2.18±2.16
>2, ≤5 38 2.29±2.15
>5 10 2.50±1.67
Immunohistochemical
ER 0.364*
Negative/reduced 25 2.61±2.37
(0, 1+, 2+)
Positive (3+) 38 2.09±1.83
PR 0.152*
Negative/reduced 27 1.88±1.72
(0, 1+, 2+)
Positive (3+) 36 2.61±2.25
Her-2 3.3×10
-6*
Negative (0, 1+, 2+) 44 1.39±1.26
Positive (3+) 19 4.40±2.03
p53 0.986*
Negative (0, 1+) 52 2.29±1.97
Positive (2+, 3+) 11 2.31±2.55
Ki-67 0.567*
≤25% 50 2.21±2.02
>25% 13 2.61±2.24
Table 1. Expression of EMP3 in 63 primary breast carcinomas
according to the clinical, histological, or biological variables
*Mann-Whitney test; 
� Kruskal-Wallis test.
EMP3, epithelial membrane protein 3; ER, estrogen receptor; PR, pro-
gesterone receptor.
p value*
EMP3 methylation
Presence N (%) Absence N (%)
Age 0.428
≤50 8 (30.8) 18 (69.2)
>50 15 (40.5) 22 (59.5)
Menopausal status 0.227
Premenopausal 10 (35.7) 18 (64.3)
Parimenopausal 0 (0.0) 3 (100.0)
Postmenopausal 13 (40.6) 19 (59.4)
Lymph node status 0.412
0 14 (41.2) 20 (58.8)
1-3 5 (41.7) 7 (58.3)
>3 4 (23.5) 13 (76.5)
Histologic grade 0.966
I 1 (33.3) 2 (66.7)
II 15 (35.7) 27 (64.3)
III 7 (38.9) 11 (61.1)
Total 23 (36.5) 40 (63.5)
Tumor type 0.745
Ductal 17 (39.5) 26 (60.5)
Lobular 2 (33.3) 4 (66.7)
Others 4 (28.6) 10 (71.4)
Tumor diameter (cm) 0.066
≤2 8 (53.3) 7 (46.7)
>2, ≤5 14 (36.8) 24 (63.2)
>5 1 (10.0) 9 (90.0)
Immunohistochemical
ER 0.641
Negative/reduced  10 (40.0) 15 (60.0)
(0, 1+, 2+)
Positive (3+) 13 (34.2) 25 (65.8)
PR 0.940
Negative/reduced 10 (37.0) 17 (63.0)
(0, 1+, 2+)
Positive (3+) 13 (36.1) 23 (63.9)
Her-2 0.081
Negative (0, 1+, 2+) 13 (29.5) 31 (70.5)
Positive (3+) 10 (52.6) 9 (47.4)
p53 1.000
Negative (0, 1+) 19 (36.5) 33 (63.5)
Positive (2+, 3+) 4 (36.4) 7 (63.6)
Ki-67 0.874
≤25 19 (38.0) 31 (62.0)
>25 4 (30.8) 9 (69.2)
Table 2. EMP3 promoter methylation distribution according to
clinical variables and immunohistochemical analysis in the 63
primary breast carcinomas
*p value obtained from χ 2 test.
EMP3, epithelial membrane protein 3; ER, estrogen receptor; PR, pro-
gesterone receptor.lation frequencies and clinical, pathological or biological
parameters (Table 2).
Relationship of methylation statuses of EMP3 with their
mRNA levels in primary breast carcinoma
Of the 23 breast carcinomas exhibiting hypermethylation
at the promoter region of EMP3, 1 (4.3%) showed low expres-
sion level, and 22 (95.7%) exhibited high EMP3 expression
levels when compared to normal breast tissues. Of the 40
breast carcinomas which the promoter region of EMP3 was
unmethylated, 3 (7.5%) showed expression levels similar to
the normal samples, and 37 (92.5%) showed high expression
levels of EMP3 compared with the control samples where
EMP3 was also unmethylated. The Mann-Whitney test show-
ed no significant difference (p=0.418) of EMP3 expression
levels between CXCL12 methylated (2.59±2.30) and un-
methylated breast carcinomas (2.13±1.91) (Fig. 2). 
DISCUSSION
Recently, the EMP3 gene was reported to have reduced
transcriptional expression in primary neuroblastoma, an
extracranial malignant solid tumor of childhood (8). Rein-
troduction of EMP3 in deficient neuroblastoma cell lines
induced lower colony formation density and tumor growth
in nude mice (8). Thus, Alaminos et al. proposed that the
EMP3 gene, located on chromosome 19q13, is a candidate
tumor suppressor gene in neuroblastomas (8). In the present
study, we used real-time quantitative RT-PCR assays to deter-
mine the mRNA expression levels of EMP3 in tumors dif-
ferent from neuroblastoma in tissue origin and age of onset:
primary breast carcinoma. Meanwhile, we sought relation-
ships between EMP3 expression status and clinical, patho-
logical, and biological parameters. However, we found that
the expression of EMP3 mRNA in primary breast carcino-
mas was significantly higher than the expression of 20 nor-
mal breast tissues (p<10-7). EMP3 overexpression in prima-
ry breast carcinomas was significantly related to histological
grade III, lymph node metastasis and strong Her-2 expres-
sion. These data are consistent with reports indicating that
overexpressions of EMP3 are significantly associated with
the invasive status of human mammary carcinoma cell lines
(3-6). The EMP3 gene was found to be significantly up-reg-
ulated (>2.0-fold) in the Her-2-overexpressing breast cancer
cell line as compared with in the normal mammary luminal
epithelial cell line (4). Taken together with previous studies
about EMP3 expression status, we hypothesized that EMP3
may display different expression pattern in different histo-
pathological tumors.
Until now, the studies on the EMP3 gene are rarely reported
and its function is largely still unknown. Recent evidence indi-
cates that EMP3 may participate in the process of cell apop-
tosis (16). EMP3 as well as the other members of the epithe-
lial membrane protein family (EMP-1, EMP-2, and PMP-22)
was found to be expressed in HEK-293 cells, which also ex-
press P2X7 receptors. The constitutive overexpression of any
of the EMPs in HEK-293 cells, through its interaction with
P2X7 receptor, led to cell blebbing, annexin V binding, and
cell death by a caspase-dependent pathway (16). Nevertheless,
EMP1, PMP-22, and EMP3 were found to be highly expressed
in invasive mammary carcinoma cells (3, 6, 17). Thus, the role
of EMP3, whether as a candidate tumor suppressor gene or
an indicator of tumor progression, remains to be established.
Absence of the unitary conception of EMP3 behavior requires
a comprehensive assessment of EMP3 expression and func-
tional mechanism in different histopathological tumors.
We sought to define a possible mechanism regulating the
expression of EMP3. Epigenetic events such as DNA methy-
lation are thought to be a major early event in tumor devel-
opment (18). A main target of the regional hypermethyla-
tion is normally CpG islands located in gene promoter regions.
The 5′ region of the EMP3 gene revealed a typical CpG island
on the start site of the transcripton. We subsequently ana-
lyzed the methylation status of EMP3 and its relationship
with mRNA expression in primary breast carcinoma. We
found that EMP3 was hypermethylated 36.5% in 63 pri-
mary breast carcinomas. But we did not find significant sta-
tistical correlation between methylation status of EMP3 and
EMP3 expression level as well as histologic subtype, tumor
grade, age and gender. Consistent with our findings, Li et al.
(9) reported that no correlation was found between transcript
level and methylation status in oligodendroglial tumors,
though all oligodendroglial tumors except 3 showed aber-
rant methylation of EMP3. Taken together, links between
EMP3 methylation status and the mode of its expression in
different tumors need further study. 
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Fig. 2. EMP3 mRNA levels were assayed by real-time PCR and
compared between tumors with hypermethylation (M) and with-
out hypermethylation (UM). In addition to the role of DNA methylation, other regula-
tory mechanisms may be involved in the regulation of EMP3.
Burmester et al. (19) tested candidate SNPs from genomic
regions that show linkage to prostate cancer susceptibility
and/or aggressiveness. The polymorphism in EMP3 changes
amino acid 125 from Val to Ile (19). Significant difference
(p<0.0001) in allele frequencies of SNP was observed for
EMP3 between prostate cancer sibships and controls (19).
And the association remained significant when cases and
controls were matched for age (19). In addition, Li et al. (9)
reported that EMP3 overexpression was associated with oligo-
dendroglial tumors retaining chromosome arms 1p and 19q,
whereas decreased EMP3 expression was associated with dele-
tion of chromosome 1p, not 19q. However, this notion is at
variance with the study from Kunitz et al. (20). They found
that low EMP3 expression was significantly associated with
19q deletion in oligodendroglial tumors, but not in astrocytic
tumors (20). Obviously, the real regulatory mechanism of
EMP3 expression remains to be elucidated. Given the vari-
able expression patterns of EMP3 in different malignant
tumors, the pathway leading to this diversity may also be
quite different, which needs to be further investigated by
additional genetic or biochemical studies.
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